Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Dr. Colla describes her current research at MD Anderson, such as developing new therapeutic approaches to MDS.
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
A drug approval specific to CMML would catalyze a surge of interest in the hematology-oncology community.
The Leukemia and Lymphoma Society's CMML Initiative hopes for dedicated CMML trials and CMML-directed therapies.
A significant number of patients receiving ivosidenib had reduced levels of voriconazole and posaconazole.
The case study included four patients with CMML who had KRAS mutations and a multitude of autoimmune diseases.
Advertisement
The study also explored the role of this combination in transitioning patients to HSCT.
An FDA committee voted that the benefits of imetelstat outweigh the risks for the treatment of anemia in lower-risk MDS.
UM171 promotes degradation of the CoREST1 complex and reduces levels of chromatin-bound MYC.
The CHMP of the European Medicines Agency recommended approval of luspatercept for transfusion-dependent anemia due to MDS.
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."
Oral decitabine plus cedazuridine is a safe and effective alternative to intravenous decitabine.
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Complete response was achieved in 14 patients (22%) in the sabatolimab group, versus 11 patients (18%) in the placebo group.
The panel shares their outlook for the future of MDS research and treatment.
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.